[Long-term Courses of Major Depressive Disorder : Characteristics, Risk Factors and the Definitional Challenge of Treatment Response]

Overview

Journal Nervenarzt

Specialty Neurology

Date 2024 Oct 14

PMID 39400712

Authors

Rebecca Paetow

Thomas Frodl

Affiliations

Soon will be listed here.

Abstract

Background: The definition of long-term courses of depression is heterogeneous. Chronic and treatment-resistant courses, in particular, represent a high-cost factor and greatly reduce the quality of life. Based on the pharmacotherapeutic treatment-resistant depression (TRD), more and more systemic approaches are becoming important.

Objective: This narrative review provides an overview of the long-term course of depressive disorders, including various definitions and influencing factors. In addition, an overview of biomarker research on treatment response with a focus on neuroimaging is presented.

Material And Methods: A selective literature search was conducted in PubMed and Google Scholar for a narrative review. Particular attention was given to larger cohort studies, systematic reviews, meta-analyses and studies on the prediction of treatment response.

Results: Chronic and treatment-resistant courses mean a relevant reduction in the quality of life and increased health risks. The assessment of treatment response is a definitional challenge: An alternative to TRD is the systemically oriented difficult to treat depression (DTD). The focus is thus moving away from symptom reduction towards controlling the level of functioning. Biomarker research for treatment response offers potential but currently mainly serves to gain theoretical knowledge.

Conclusion: Recording the long-term course of depressive illnesses is important, but also complex. Clinical interventions should therefore include a continuous monitoring and the focus on maintaining the quality of life.

References

Bschor T, Kern H, Henssler J, Baethge C . Switching the Antidepressant After Nonresponse in Adults With Major Depression: A Systematic Literature Search and Meta-Analysis. J Clin Psychiatry. 2016; 79(1). DOI: 10.4088/JCP.16r10749. View

Ren F, Ma Y, Zhu X, Guo R, Wang J, He L . Pharmacogenetic association of bi- and triallelic polymorphisms of SLC6A4 with antidepressant response in major depressive disorder. J Affect Disord. 2020; 273:254-264. DOI: 10.1016/j.jad.2020.04.058. View

Judd L, Akiskal H, Maser J, Zeller P, Endicott J, Coryell W . A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry. 1998; 55(8):694-700. DOI: 10.1001/archpsyc.55.8.694. View

Frodl T, Meisenzahl E, Zetzsche T, Hohne T, Banac S, Schorr C . Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up. J Clin Psychiatry. 2004; 65(4):492-9. DOI: 10.4088/jcp.v65n0407. View

Iancu S, Wong Y, Rhebergen D, van Balkom A, Batelaan N . Long-term disability in major depressive disorder: a 6-year follow-up study. Psychol Med. 2019; 50(10):1644-1652. DOI: 10.1017/S0033291719001612. View

Keitner G, Mansfield A . Management of treatment-resistant depression. Psychiatr Clin North Am. 2012; 35(1):249-65. DOI: 10.1016/j.psc.2011.11.004. View

Rush A, Sackeim H, Conway C, Bunker M, Hollon S, Demyttenaere K . Clinical research challenges posed by difficult-to-treat depression. Psychol Med. 2022; 52(3):419-432. PMC: 8883824. DOI: 10.1017/S0033291721004943. View

Fu C, Williams S, Cleare A, Scott J, Mitterschiffthaler M, Walsh N . Neural responses to sad facial expressions in major depression following cognitive behavioral therapy. Biol Psychiatry. 2008; 64(6):505-12. DOI: 10.1016/j.biopsych.2008.04.033. View

Jacobi F, Hofler M, Strehle J, Mack S, Gerschler A, Scholl L . [Mental disorders in the general population : Study on the health of adults in Germany and the additional module mental health (DEGS1-MH)]. Nervenarzt. 2014; 85(1):77-87. DOI: 10.1007/s00115-013-3961-y. View

10.

Caetano S, Hatch J, Brambilla P, Sassi R, Nicoletti M, Mallinger A . Anatomical MRI study of hippocampus and amygdala in patients with current and remitted major depression. Psychiatry Res. 2004; 132(2):141-7. DOI: 10.1016/j.pscychresns.2004.08.002. View

11.

Bschor T, Bauer M, Adli M . Chronic and treatment resistant depression: diagnosis and stepwise therapy. Dtsch Arztebl Int. 2014; 111(45):766-75. PMC: 4260060. DOI: 10.3238/arztebl.2014.0766. View

12.

Murphy J, Byrne G . Prevalence and correlates of the proposed DSM-5 diagnosis of Chronic Depressive Disorder. J Affect Disord. 2012; 139(2):172-80. DOI: 10.1016/j.jad.2012.01.033. View

13.

Vogelbacher C, Mobius T, Sommer J, Schuster V, Dannlowski U, Kircher T . The Marburg-Münster Affective Disorders Cohort Study (MACS): A quality assurance protocol for MR neuroimaging data. Neuroimage. 2018; 172:450-460. DOI: 10.1016/j.neuroimage.2018.01.079. View

14.

Cipriani A, Furukawa T, Salanti G, Chaimani A, Atkinson L, Ogawa Y . Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018; 391(10128):1357-1366. PMC: 5889788. DOI: 10.1016/S0140-6736(17)32802-7. View

15.

McIntyre R, Alsuwaidan M, Baune B, Berk M, Demyttenaere K, Goldberg J . Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023; 22(3):394-412. PMC: 10503923. DOI: 10.1002/wps.21120. View

16.

van Tol M, van der Wee N, Veltman D . Fifteen years of NESDA Neuroimaging: An overview of results related to clinical profile and bio-social risk factors of major depressive disorder and common anxiety disorders. J Affect Disord. 2021; 289:31-45. DOI: 10.1016/j.jad.2021.04.009. View

17.

Kautzky A, Baldinger P, Souery D, Montgomery S, Mendlewicz J, Zohar J . The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression. Eur Neuropsychopharmacol. 2015; 25(4):441-53. DOI: 10.1016/j.euroneuro.2015.01.001. View

18.

Mulder R, Joyce P, Frampton C . Personality disorders improve in patients treated for major depression. Acta Psychiatr Scand. 2009; 122(3):219-25. DOI: 10.1111/j.1600-0447.2009.01502.x. View

19.

Heerlein K, Young A, Otte C, Frodl T, Degraeve G, Hagedoorn W . Real-world evidence from a European cohort study of patients with treatment resistant depression: Baseline patient characteristics. J Affect Disord. 2021; 283:115-122. DOI: 10.1016/j.jad.2020.11.124. View

20.

Jaffe D, Rive B, Denee T . The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study. BMC Psychiatry. 2019; 19(1):247. PMC: 6686569. DOI: 10.1186/s12888-019-2222-4. View